Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat + Pembrolizumab in Endometrial Carcinoma
NCT03310567Phase 2Withdrawn
- Sponsor
- Fox Chase Cancer Center
- Start
- Sep 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of epacadostat in endometrial carcinoma, sponsored by Fox Chase Cancer Center. Planned start Sep 2018; status: withdrawn.
02
Drugs
epacadostat
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT03310567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03310567.